Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

The business is maturing, but there's still lots to like about this medical robotics leader.

Intuitive Surgical Sutures Up Its Wounds With a Big Stock Buyback

Johnson & Johnson

Stryker

As surgeries bounce back toward pre-pandemic levels, these three companies should benefit.

3 Medical Stocks On the Rebound

Investors are applauding the big stock buyback by the robotic surgical-systems maker.

Why Intuitive Surgical Stock Is Jumping Today

Intuitive Surgical (NASDAQ: ISRG ) stock is rising higher on Tuesday after entering into an accelerated share repurchase agreement. According to a filing with the U.S. Securities and Exchange Commission (SEC), it's agreed to buy back $1 billion worth of ISRG stock from Citibank.

What Is Going on With Intuitive Surgical (ISRG) Stock Today?

Shares of Intuitive Surgical Inc. ISRG, +0.81% surged 4.9% in premarket trading Tuesday, after the surgical systems and instruments for invasive surgeries announced a $1 billion accelerated stock repurchase agreement (ASR). That represents 1.3% of the companies market capitalization of $77.84 billion as of Monday's close.

Intuitive Surgical stock surges after $1 billion ASR agreement

Intuitive offered clues about the future in its recent earnings report.

Is It Time to Buy This Beaten-Down Growth Stock?

Intuitive Surgical stock (NASDAQ: ISRG) has seen an 11% rise in a month, while it is up 14% in a week.

What's Next For Intuitive Surgical Stock After Upbeat Q3?

The robotic surgical specialist beat expectations and is making a huge investment in a healthy outcome.

Intuitive Surgical is Investing $1 Billion -- in Itself

Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

Lockheed Martin

Netflix

United Continental Hlds

These reports indicate encouraging trends amidst the depressing economic backdrop.

These Stocks Have Popped: Here's Why

SUNNYVALE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Today, Intuitive announced that it has become the largest provider of robotic-assisted surgical technology training to be accredited by the Royal College of Surgeons of England (RCS England).

Intuitive becomes largest robotic-assisted surgery provider to be accredited by the Royal College of Surgeons of England

The robotic surgery leader's third-quarter results easily topped Wall Street's forecasts.

Why Intuitive Surgical Stock Is Bolting Higher Today

Intuitive Surgical Inc. ISRG, +11.65% shares rallied Wednesday after the surgical robotics company's quarterly results topped Wall Street estimates. Intuitive Surgical shares rose more than 12% to an intraday high of $220.98 Wednesday Late Tuesday, the company reported third-quarter net income of $324 million, or 90 cents a share, compared with $380.5 million, or $1.04 a share, in the year-ago period.

Intuitive Surgical stock rallies more than 10% following earnings beat

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q3 2022 Earnings Conference Call October 18, 2022 4:30 PM ET Company Participants Brian King - Head, Investor Relations Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Amit Hazan - Goldman Sachs Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Richard Newitter - Truist Jayson Bedford - Raymond James Matt Taylor - Jefferies Adam Maeder - Piper Sandler Matt Miksic - Barclays Drew Ranieri - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to the Intuitive Third Quarter Earnings Release Call.

Intuitive Surgical, Inc. (ISRG) Q3 2022 Earnings Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 8.18% and 2.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Surpasses Q3 Earnings and Revenue Estimates

Intuitive Surgical easily beat quarterly estimates on Tuesday, helped by strong procedure growth, and ISRG stock jumped. The post Robotic Surgery Behemoth Intuitive Surgical Crushes Quarterly Forecasts; Shares Jump appeared first on Investor's Business Daily.

Robotic Surgery Behemoth Intuitive Surgical Crushes Quarterly Forecasts; Shares Jump

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q3 Earnings?

AbbVie

Amazon

Texas Instruments

It's time to make a wishlist -- and just in time for the holidays!

4 Stocks I Own and Will Buy More of if the Market Crashes

Digital Realty Trust

Each of these companies is big and getting bigger, and their prices are appealing, too.

$5,000 Invested in These 3 Stocks Could Make You Rich Over the Next 20 Years

Broadcom

Okta

These game-changing stocks are begging to be bought following a 34% plunge in the Nasdaq Composite.

Nasdaq Bear Market: 5 Colossal Growth Stocks You'll Regret Not Buying On the Dip

AMN Healthcare Services

Vertex Pharmaceuticals

Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.

3 Medical Stocks to Buy in 2022 for Long-Term Resilience

Intuitive Surgical (NASDAQ: ISRG) is scheduled to report its Q3 2022 results on Tuesday, October 18.

What To Expect From Intuitive Surgical's Q3?

The tech giant has had a good run over the past 10 years, but I'd go with these stocks for the next 10.

Prediction: 2 Underrated Stocks That Will Outperform Amazon Over the Next Decade

Intuitive Surgical enjoys a wide moat in the robotic-assisted-surgery space.

Down Nearly 50%, Is This Growth Stock Still a Buy?

FANUC Corp

IPG Photonics

iRhythm Technologies

NVIDIA

UiPath

Teradyne

The robotics industry has been growing at an incredible pace, and the computing power needed for these mechatronic devices is getting cheaper by the day. The increased computing power and data handling capabilities of mechatronic devices are allowing them new actions that previously weren't possible for humans.

News for Intuitive Surgical Stock (ISRG)